MRUS - Merus Stock: Rally Seems Overdone
2024-01-23 17:10:35 ET
Summary
- Merus N.V. shares have remained strong despite negative safety news about its MCLA-129 program, as attention shifts to promising candidates petosemtamab and zenocutuzumab.
- Petosemtamab shows solid overall response rates for head and neck cancer, while zenocutuzumab is expected to file for BLA in mid-2024 for NGR1+ cancers.
- Merus has a strong balance sheet and multiple collaborations, with analyst firms optimistic about its prospects and a median price target objective of $46 a share.
- An analysis around Merus N.V. follows in the paragraphs below.
Impatience can cause wise people to do foolish things ."? Janette Oke.
Shares of bispecific cancer therapy concern Merus N.V. ( MRUS ) shook off negative safety news regarding its MCLA-129 program, as the focus turned to two other promising oncology candidates. Petosemtamab for head and neck cancer and zenocutuzumab for NGR1+ cancers both demonstrated solid overall response rates, with the latter looking poised for a mid-2024 BLA filing. With multiple collaborations and a balance sheet able to fund operations into 2027 without an approval, Merus merited a deeper dive. An analysis follows below....
Merus Stock: Rally Seems Overdone